Insilico Medicine receives Health Innovation Trailblazer Award: Industry from UAE Genetic Diseases Association

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announces that it has been awarded Health Innovation Trailblazer Award: Industry by the UAE Genetic Diseases Association for its end-to-end drug discovery platform Pharma.AI and diversified novel drug pipeline, which acknowledges the company’s innovative advancements improving the quality of life of patients, families, and caregivers, as well as its commitment to leveraging artificial intelligence to address complex genetic diseases.

Among the categories of UAE International Genomics Awards 2024 given by UAE Genetics Diseases Association, Health Innovation Trailblazer Award: Industry celebrates excellence and innovation in the field of genetics, with a focus on cutting-edge industries including genomic medicine, artificial intelligence & machine, and nanotechnology.

Khadija Alawi, PhD, Senior Biology Analyst at Insilico Medicine, received the award on behalf of the Insilico team, “It has been incredibly fruitful and rewarding working with the R&D colleagues and AI platforms at Insilico Medicine. With the help of generative AI and large language models (LLMs), we hope to further accelerate novel treatments against diseases as well as the aging process.” Experienced in diverse therapeutic areas including gene therapies and small molecules, Dr. Alawi is passionate about the potential of applying AI to interpret complex biological data from patients, and for patients.

Driven by innovation aspirations powered by artificial intelligence, Insilico made multiple achievements in the UAE. In August 2022, Insilico closed its Series D2 round led by Saudi Aramco-backed Prosperity7 Ventures, bringing the total Series D financing to $95 million, despite an uncertain market. In September 2022, Insilico signed a Memorandum of Understanding (MoU) with Saudi Arabia’s Ministry of Investment (MISA) to support the development of a robust AI-driven biotech in Saudi Arabia. In February 2023, Insilico opened the region’s largest AI-powered biotechnology research center in Abu Dhabi, in order to expand the capabilities of proprietary Pharma.AI drug discovery platform, and to support the digital transformation of healthcare in the region..

“I am deeply honored that Insilico has been recognized, again, for all the hard work and achievements produced with the combination of artificial and human intelligence,” says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “This award motivates us to move forward in transforming and accelerating drug discovery, and we look forward to contributing more to this field and bringing about positive change in global healthcare.”

Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets and has received clinical trial approval for seven molecules. In March 2024, the Company published a paper in Nature Biotechnology that discloses the raw experimental data and the preclinical and clinical evaluation of its lead drug – a potentially first-in-class TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis discovered and designed using generative AI currently in Phase II trials with patients.

About Insilico Medicine

Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com